What this pack is
Plavix is the brand name in this record; clopidogrel is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
PlavixGeneric nameclopidogrel
Mainland China pack-name cue波立维®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
FDA's PLAVIX prescribing information describes clopidogrel's active metabolite as binding irreversibly to P2Y12-class ADP receptors on platelets, inhibiting platelet activation and aggregation. This helps explain “antiplatelet”; it cannot decide whether an individual should start, stop, combine medicines, manage a procedure or resume treatment.
Read source: United States ↗Current regulatory record · reviewed 2026-08-30More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 波立维®
- International brand name
- Plavix
- Generic name
- clopidogrel
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:波立维®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v5, published 11 Jun 2025
75 mg per tablet; 90-tablet bottle
- Product code
- NDC 0024-1171-90
- Form and route
- PLAVIX clopidogrel film-coated oral tablet · oral
- Container
- 90-tablet bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-20; actual marketing, stock and availability are not established.
- clopidogrel
- 75 mglabelled amount per tablet; not an individual's tablet count, interruption or switching rule
- Package
- 90 tablets per bottle
- Labelled appearance
- pink · round biconvex film-coated tablet · imprint 75 / 1171
United States label · DailyMed SPL v5, effective 30 May 2025
300 mg per tablet; 30-tablet blister-card carton
- Product code
- NDC 0024-1332-30
- Form and route
- PLAVIX clopidogrel film-coated oral tablet · oral (exact-product identity field)
- Container
- blister-card carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-30; actual marketing, stock and availability are not established.
- clopidogrel
- 300 mglabelled amount per tablet; not permission to assemble a loading amount or conversion from multiple 75 mg tablets
- Package
- 30 tablets per carton
- Labelled appearance
- pink · oblong film-coated tablet · imprint 300 / 1332Unscored in this labelled presentation
CN · Sanofi China locally produced leaflet, revised 1 Sep 2025
Clopidogrel 75 mg per tablet; hard double-aluminium packs of 7, 14, 28 or 90 tablets per carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NMPA approval No. H20056410
- Form and route
- PLAVIX clopidogrel bisulfate film-coated tablet (locally produced in China) · oral (Mainland China leaflet product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- clopidogrel (provided as clopidogrel bisulfate)
- 75 mgMainland China leaflet amount per tablet; not an individual's tablet count, loading, interruption or switching instruction
CN · Sanofi China imported-product leaflet, revised 22 May 2025
Clopidogrel 75 mg per tablet; double-aluminium blister packs of 7, 28 or 90 tablets per carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NMPA approval No. HJ20171237 (small pack) / HJ20171238 (large pack)
- Form and route
- PLAVIX clopidogrel bisulfate film-coated tablet (imported into China) · oral (Mainland China leaflet product-identity field)
- Listing review
- Cited public label display reviewed 2026-08-30; actual marketing, stock and availability are not established.
- clopidogrel (provided as clopidogrel bisulfate)
- 75 mgMainland China leaflet amount per tablet; not an individual's tablet count, loading, interruption or switching instruction
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
PLAVIX / 波立维 label reading: separate market, 75/300 mg and single-ingredient/combination products
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The current U.S. PLAVIX label lists 75 mg and 300 mg tablets. Sanofi China's current product page lists both imported and locally produced 波立维 75 mg tablets, each with a distinct leaflet, pack description and approval number. CoPlavix / 多立维 also contains aspirin and is a separate combination product. This module explains product identity and safety boundaries; it does not generate an individual tablet count, loading amount, interruption, procedure, combination, switching or genetic-testing plan.
- First identify whether the pack is U.S. PLAVIX 75 mg/300 mg, imported China-market 波立维 75 mg, or locally produced China-market 波立维 75 mg. A shared brand and milligram number do not erase approval-number, pack-count, holder or leaflet-date differences, and 300 mg is not webpage permission to assemble an amount from multiple 75 mg tablets.
- CoPlavix / 多立维 contains aspirin as an additional ingredient and is a separate combination product. Seeing ‘clopidogrel 75 mg’ does not make single-ingredient PLAVIX and a clopidogrel/aspirin combination the same medicine, and it does not permit self-combination, substitution or make-up use.
- The U.S. and China leaflets discuss CYP2C19-related metabolic differences. This is not a conclusion that everyone needs whole-genome screening. Whether a test is needed, which test, how an existing result should be interpreted and whether it changes a choice require the indication, event history, target-market label and complete medicine list to be assessed by the responsible team.
- The current U.S. label explicitly identifies omeprazole or esomeprazole as CYP2C19-inhibitor co-medication cues to avoid and notes that separating administration by 12 hours did not remove the observed effect. This should prompt review of the stomach medicine and full list by a pharmacist or prescriber, not abrupt self-stopping, timing changes or substitution of either medicine.
- When aspirin, warfarin or another anticoagulant/antiplatelet medicine, an NSAID pain medicine such as ibuprofen/naproxen, or an SSRI/SNRI is on the same list, the label identifies bleeding risk for priority review. Black stool, vomiting blood, bleeding that will not stop, or symptoms after a fall/head injury require local urgent care; do not wait for a webpage to decide.
- Before surgery, dental extraction or another invasive procedure, do not copy a number of interruption days from the label yourself. The PLAVIX label also warns that discontinuation increases cardiovascular-event risk; whether to interrupt, when to do so and when to resume require instructions for the individual and specific procedure from the prescribing and procedural teams.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-30
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
- See original document · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. PLAVIX clopidogrel public label (Sanofi-Aventis; effective 30 May 2025) ↗Current regulatory record · reviewed 2026-08-30
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- Public product-record source · See original document · Public product record · 2026-08-30Sanofi China: locally produced PLAVIX clopidogrel hydrogen sulfate 75 mg tablet leaflet (revised 1 Sep 2025) ↗reviewed 2026-08-30
- Public product-record source · See original document · Public product record · 2026-08-30Sanofi China: imported PLAVIX clopidogrel hydrogen sulfate 75 mg tablet leaflet (revised 22 May 2025) ↗reviewed 2026-08-30
Reviewed official safety records
A dated record is not automatically a current alert. Read the named product, form, batch, market, date and source type before treating it as relevant.
- FDA pharmacogenomic label record: clopidogrel and CYP2C192025-12 · FDA’s Table of Pharmacogenomic Biomarkers in Drug Labeling lists clopidogrel (Plavix) with CYP2C19-related labeling information. The table is a U.S. regulator index to where genomic information appears in labeling; it does not mean every user needs screening, that a tested person should self-change a dose, or that another medicine may be substituted independently. Whether to test, how to interpret a result and how it relates to other medicines must be reviewed with the exact product, indication, current label and complete medicine list by the prescribing team or pharmacist.Primary-source record (open linked document) ↗reviewed 2026-08-22
- FDA Drug Safety Communication: review of mortality risk with long-term Plavix/clopidogrel treatment2015-11-06 · In a U.S. Drug Safety Communication issued on 2015-11-06, FDA said its review of the DAPT trial and other long-term clinical trials did not show that clopidogrel increases or decreases overall risk of death in people with, or at risk for, heart disease, and did not suggest increased cancer or cancer-death risk. The communication concerns evidence for long-term antiplatelet treatment in a specific U.S. trial context. It cannot determine an individual’s bleeding, clotting, cancer, treatment duration, need for genetic testing or co-medication plan, and it does not support self-stopping Plavix/clopidogrel or self-alternating, adding or replacing it with aspirin, anticoagulants, pain medicines or another product. Bleeding, chest pain, neurological symptoms or another acute concern needs local emergency support and review of the complete medicine list with the prescribing team or pharmacist.Hong Kong Department of Health Drug Office: official safety-alert archive reproducing the FDA 6 Nov 2015 Plavix (clopidogrel) long-term-treatment communication ↗reviewed 2026-08-22
Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Plavix (clopidogrel). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Plavix is the brand in this record and clopidogrel is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. PLAVIX clopidogrel public label (Sanofi-Aventis; effective 30 May 2025) ↗Current regulatory record · reviewed 2026-08-30
- Sanofi China: locally produced PLAVIX clopidogrel hydrogen sulfate 75 mg tablet leaflet (revised 1 Sep 2025) ↗reviewed 2026-08-30
- Sanofi China: imported PLAVIX clopidogrel hydrogen sulfate 75 mg tablet leaflet (revised 22 May 2025) ↗reviewed 2026-08-30
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When NEXIUM / esomeprazole is on the same list: review the complete list first
The U.S. PLAVIX public label names omeprazole or esomeprazole as co-medication cues that need review. This card only signals that every actual pack, OTC product and supplement should be reviewed by a pharmacist or prescriber; it does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Nexium / esomeprazole record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗Current regulatory record · reviewed 2026-08-30HOW IT WORKS · NOT A TREATMENT PLAN
How clopidogrel works: its active metabolite acts on platelet P2Y12 receptors
- “Platelet aggregation” can be understood as part of the process in which platelets stick together. The mechanism describes one receptor pathway; it does not mean bleeding, chest pain, stroke-like symptoms or an upcoming procedure can be self-managed from a webpage.
- The label says clopidogrel requires CYP450 metabolism to form its active metabolite and specifically identifies CYP2C19-related variation. It does not mean everyone should self-order testing or change medicines based on a result; an existing report needs professional interpretation with the indication, complete medicine list and current local label.
- With aspirin, anticoagulants, pain medicines, herbs, stomach medicines or another “blood-thinning” product, risk and benefit cannot be judged merely from whether mechanisms are the same or different. Especially with unusual bleeding, a fall or head injury, and before or after surgery or dental work, follow the responsible team's specific instructions rather than self-missing, making up, combining or stopping doses.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. PLAVIX clopidogrel public label (Sanofi-Aventis; effective 30 May 2025) ↗Current regulatory record · reviewed 2026-08-30
- Sanofi China: imported and locally produced PLAVIX 75 mg product page ↗reviewed 2026-08-30
- Sanofi China: locally produced PLAVIX clopidogrel hydrogen sulfate 75 mg tablet leaflet (revised 1 Sep 2025) ↗reviewed 2026-08-30
- Sanofi China: imported PLAVIX clopidogrel hydrogen sulfate 75 mg tablet leaflet (revised 22 May 2025) ↗reviewed 2026-08-30
- Sanofi China: CoPlavix clopidogrel-and-aspirin combination product page (identity exclusion for single-ingredient PLAVIX) ↗reviewed 2026-08-30
- FDA Drugs@FDA: PLAVIX NDA 020839 search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Plavixclopidogrel
This page includes an exact current U.S. public-label package panel for Plavix, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
LABEL USE SNAPSHOT
What the cited U.S. label covers
U.S. FDA label snapshot, revised Sep 2022: for acute coronary syndrome and for people with recent myocardial infarction, recent stroke or established peripheral arterial disease, to reduce myocardial infarction and stroke.
It is source-reading context, not an individual diagnosis, prescription, substitution or purchasing recommendation. Check the current label in the target market.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the FDA label
The FDA label archive linked here lists Initial U.S. Approval: 1997. This historical locator is not a conclusion about current approval, availability, holder or another market.
FDA: PLAVIX label archive ↗FDA label archive version
This page links the 2022 FDA label archive as a traceable reading entry point. Current labeling, strength, indication and safety information require separate verification against the target market’s current document.
FDA: PLAVIX label archive ↗
MARKET SCOPE
Market-record boundary
United States
Public label archive linkedOnly the FDA document listed on this page is linked.
Mainland China, EU, Japan
Market record not establishedNo local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. label archive.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 波立维®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Does a label archive represent current product information?
Not automatically. The archive locates a source; each point needs verification against the target market’s current official label.
Why are price and originator/generic conclusions not shown?
Those conclusions require separately complete and human-reviewed product, dosage-form, strength, pack, market, date and primary-record fields; one label file is insufficient.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.